Extraintestinal gastrointestinal stromal tumor (EGIST) is a rare mesenchymal neoplasm developing in the mesentery, omentum, retroperitoneum, or peritoneal cavity outside the gastrointestinal tract. It accounts for approximately 5-10% of all GISTs. EGISTs share the same immunohistochemical profile as intestinal GISTs: CD117 (KIT) and DOG1 positivity, KIT or PDGFRA gene mutations. Pathologically thought to originate from interstitial cells of Cajal, though their development outside the GI tract makes this origin controversial. Surgical resection is first-line treatment, with imatinib (tyrosine kinase inhibitor) used in high-risk or metastatic disease. Prognosis depends on tumor size, mitotic index, and mutation type.
Age Range
40-80
Peak Age
60
Gender
Equal
Prevalence
Rare
The pathogenesis of EGISTs is based on gain-of-function mutations in KIT or PDGFRA proto-oncogenes. KIT mutations (most commonly exon 11, less commonly exons 9, 13, 17) lead to ligand-independent tyrosine kinase activation triggering uncontrolled cell proliferation, apoptosis inhibition, and angiogenesis stimulation. PDGFRA mutations (most commonly exon 18 — D842V) work through similar mechanisms. Intense vascularity and enhancement reflect neoangiogenesis from KIT signaling pathway increasing VEGF expression. The peripheral enhancement and central necrosis pattern on CT reflects the inability to supply the central region during rapid tumor growth — peripheral viable tumor tissue enhances while central coagulation necrosis develops. T2 hyperintensity on MRI reflects myxoid stroma and free water content in tumor tissue. After imatinib treatment, tumor density decrease (on CT), size decrease, or cystic degeneration ('Choi criteria') are observed — reflecting vascular regression and tumor necrosis from tyrosine kinase inhibition.
A large solid mass in the mesentery or omentum without demonstrable direct GI tract connection, showing peripheral enhancement and central necrosis pattern, is the most characteristic imaging finding for EGIST. This combination reflects KIT mutation-mediated neoangiogenesis and rapid tumor growth.
Contrast-enhanced CT demonstrates a large (frequently >5 cm) mass in mesenteric/omental/retroperitoneal location. Small EGISTs (<5 cm) may show relatively homogeneous enhancement, while large masses show typical peripheral enhancement + central necrosis/hemorrhage pattern. Enhancement is generally moderate-to-prominent. Intratumoral hemorrhage, cystic degeneration, and rarely ulceration or cavitation may be seen. Inability to demonstrate direct GI tract connection supports EGIST diagnosis; however, large exophytic intestinal GISTs can mimic EGIST.
Report Sentence
Large solid mass in the mesentery/omentum demonstrating peripheral enhancement and central necrosis pattern without direct GI tract connection; extraintestinal GIST (EGIST) should be considered in the differential diagnosis.
Prominent hypervascular enhancement in solid components may be observed in the arterial phase. Enhancement is generally heterogeneous — viable tumor tissue enhances intensely while necrotic areas do not. Arterial phase is particularly useful for evaluating the vascular pattern of EGIST: feeding vessels and early-enhancing solid components are detected. In active bleeding or tumor rupture, contrast extravasation may be seen in the arterial phase.
Report Sentence
Prominent enhancement in solid components of the mass in the arterial phase.
On T2-weighted MRI, EGIST demonstrates heterogeneous and generally high signal intensity. Solid components show intermediate-to-high T2 signal (myxoid stroma), cystic/necrotic areas very high T2 signal, and hemorrhage areas variable signal depending on stage. On T1, solid components generally show low-intermediate signal while hemorrhage areas are hyperintense. Contrast-enhanced series demonstrate peripheral enhancement + central necrosis pattern similar to CT.
Report Sentence
The mesenteric/omental mass demonstrates heterogeneous high signal on T2-weighted MRI sequences containing solid, cystic, and hemorrhagic components.
Viable tumor tissue demonstrates diffusion restriction on DWI — hyperintense at high b-values and hypointense on ADC map. Necrotic areas do not show diffusion restriction. DWI is particularly valuable in imatinib treatment response evaluation: pre-treatment low ADC values increase post-treatment (cellularity decrease from tumor necrosis). DWI-ADC change may be an early indicator of treatment response along with Choi criteria.
Report Sentence
Viable tumor components demonstrate diffusion restriction on DWI; ADC values have been recorded as baseline for treatment response monitoring.
On US, a large, heterogeneous solid mass in the mesentery or omentum is observed. Internal structure is variable: solid areas hypoechoic or isoechoic, cystic/necrotic areas may show anechoic or complex echogenic content. Mass margins are generally smooth but may be irregular in large masses. Hemorrhagic areas show heterogeneous echogenicity.
Report Sentence
Large, heterogeneous solid mass in the mesentery/omentum on US; further evaluation with CT/MRI is recommended.
EGIST generally shows moderate-to-intense FDG uptake on FDG PET-CT (SUVmax typically 5-15). High-grade tumors show more intense uptake, low-grade tumors show less. PET-CT is considered the gold standard for imatinib treatment response evaluation: FDG uptake decreases dramatically in responding tumors — sometimes even within the first week of treatment. Size reduction may take months while metabolic response can be detected within days.
Report Sentence
The mesenteric/omental mass demonstrates intense FDG uptake on PET-CT (SUVmax: ___); recorded as baseline for treatment response monitoring.
Criteria
GIST located in the mesentery not arising from intestinal wall. Most common EGIST location. Usually presents as a large mass.
Distinct Features
Jejunal/ileal mesentery most common. Inability to demonstrate GI lumen connection is diagnostic. Differentiation from exophytic intestinal GIST may be difficult — surgical exploration provides definitive distinction.
Criteria
GIST located in the greater or lesser omentum. Second most common EGIST location.
Distinct Features
May show omental cake-like diffuse involvement mimicking peritoneal carcinomatosis. CD117/DOG1 immunohistochemistry is distinguishing.
Criteria
GIST located in the retroperitoneum not arising from GI tract or other organs. Rarest EGIST location.
Distinct Features
Requires differential diagnosis with retroperitoneal sarcoma, paraganglioma, and lymphoma. CD117/DOG1 positivity confirms diagnosis. KIT/PDGFRA mutation analysis determines imatinib sensitivity.
Distinguishing Feature
Desmoid tumor shows variable T2 signal (collagen = low signal areas), central necrosis is rare with progressive enhancement pattern. EGIST is more heterogeneous with prominent central necrosis and typical peripheral enhancement. Desmoid is KIT/DOG1 negative, nuclear beta-catenin positive.
Distinguishing Feature
Peritoneal mesothelioma typically shows diffuse peritoneal thickening and nodular implants; EGIST is a localized mass. Mesothelioma may have asbestos exposure history and pleural plaques. IHC: mesothelioma calretinin/WT-1 positive, EGIST KIT/DOG1 positive.
Distinguishing Feature
Mesenteric Castleman disease shows homogeneous intense enhancement with feeding vessel sign; EGIST shows more heterogeneous enhancement with prominent central necrosis. Castleman is KIT negative with negative tumor markers.
Distinguishing Feature
Peritoneal carcinomatosis shows diffuse peritoneal nodules, omental cake, and ascites; EGIST is a localized mass. Primary tumor history and histopathological distinction (KIT/DOG1 vs epithelial markers) determine diagnosis.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralEGIST treatment consists of surgical resection in localized disease and imatinib (tyrosine kinase inhibitor) combination in high-risk or metastatic disease. Surgery aims for R0 resection with intact capsule — rupture or fragmentation increases peritoneal dissemination risk. Imatinib sensitivity depends on mutation type: KIT exon 11 has the best response, PDGFRA D842V is generally imatinib resistant (avapritinib sensitive). Choi criteria (density + size) are superior to RECIST for treatment response evaluation as size reduction may be slow after imatinib while density decrease is detected early. Risk stratification (size, mitotic index, location) determines adjuvant imatinib decision.
Extra-intestinal GIST is rare but clinically significant. It responds to imatinib (tyrosine kinase inhibitor) therapy. Surgical resection is the primary treatment. Treatment response is monitored by CT showing size reduction and cystic change (Choi criteria). Peritoneal and liver metastases may develop.